Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
- 17 December 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 147 (3), 876-877
- https://doi.org/10.1016/j.jaci.2020.12.003
Abstract
No abstract availableFunding Information
- UCLA AIDS Institute
- Jeffrey Modell Foundation
This publication has 7 references indexed in Scilit:
- Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigensImmunotherapy, 2020
- A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoVScience, 2020
- Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19International Journal of Antimicrobial Agents, 2020
- Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19Journal of Infection, 2020
- High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019Open Forum Infectious Diseases, 2020
- Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A reviewJournal of Infection and Public Health, 2018
- Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza VirusesThe Journal of Infectious Diseases, 2014